96 related articles for article (PubMed ID: 29100168)
21. Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.
Zhong G; Li HK; Shan T; Zhang N
Genet Mol Res; 2015 Dec; 14(4):17228-34. PubMed ID: 26681216
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
23. ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.
Zhang Y; Cao S; Zhuang C; Chen J; Chen X; Sun H; Lin S; Lin B
J Ovarian Res; 2021 Jun; 14(1):80. PubMed ID: 34148553
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
Meulendijks D; Rozeman EA; Cats A; Sikorska K; Joerger M; Deenen MJ; Beijnen JH; Schellens JHM
Pharmacogenomics J; 2017 Oct; 17(5):441-451. PubMed ID: 27995989
[TBL] [Abstract][Full Text] [Related]
26. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
27. Are glutathione S-transferase polymorphisms (GSTM1, GSTT1) associated with primary open angle glaucoma? A meta-analysis.
Lu Y; Shi Y; Yin J; Huang Z
Gene; 2013 Sep; 527(1):311-5. PubMed ID: 23827458
[TBL] [Abstract][Full Text] [Related]
28. GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis.
Hu XY; Huang XY; Ma J; Zuo Y; Luo NB; Lai SL; Su DK
Tumour Biol; 2016 Jan; 37(1):151-62. PubMed ID: 26577857
[TBL] [Abstract][Full Text] [Related]
29. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
[TBL] [Abstract][Full Text] [Related]
30. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
31. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
[No Abstract] [Full Text] [Related]
32. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.
Wang MJ; Zhu Y; Guo XJ; Tian ZZ
Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406
[TBL] [Abstract][Full Text] [Related]
33. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.
Beeghly A; Katsaros D; Chen H; Fracchioli S; Zhang Y; Massobrio M; Risch H; Jones B; Yu H
Gynecol Oncol; 2006 Feb; 100(2):330-7. PubMed ID: 16199080
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Yu SN; Liu GF; Li XF; Fu BH; Dong LX; Zhang SH
J Cell Biochem; 2017 Dec; 118(12):4782-4791. PubMed ID: 28520216
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
[TBL] [Abstract][Full Text] [Related]
36. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
[TBL] [Abstract][Full Text] [Related]
37. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
38. Genetic variability of DNA repair mechanisms influences treatment outcome of gastric cancer.
Ding C; Zhang H; Chen K; Zhao C; Gao J
Oncol Lett; 2015 Oct; 10(4):1997-2002. PubMed ID: 26622786
[TBL] [Abstract][Full Text] [Related]
39. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival.
Nagle CM; Chenevix-Trench G; Spurdle AB; Webb PM
Eur J Cancer; 2007 Jan; 43(2):283-90. PubMed ID: 17084623
[TBL] [Abstract][Full Text] [Related]
40. Genetic Polymorphism of GSTM1 and GSTT1 and Risk of Prostatic Carcinoma - a Meta-analysis of 7,281 Prostate Cancer Cases and 9,082 Healthy Controls.
Malik SS; Kazmi Z; Fatima I; Shabbir R; Perveen S; Masood N
Asian Pac J Cancer Prev; 2016; 17(5):2629-35. PubMed ID: 27268642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
